Trials / Completed
CompletedNCT04316689
First-in-human Study of S-588210 (S-488210+S-488211)
Open-label, Phase 1 Study of S-488210/S-488211 to Evaluate the Safety and Tolerability in Patients With Unresectable Recurrent and/or Metastatic Solid Tumor
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Shionogi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective is to evaluate the safety and tolerability of S-588210 (S-488210+S-488211) in patients with unresectable recurrent and/or metastatic solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | S-488210 | S-488210 is a freeze-dried injectable formulation containing the following three peptides, S-488201 (a URLC10-derived peptide), S-488202 (a CDCA1-derived peptide) and S-488203 (a KOC1-derived peptide). |
| BIOLOGICAL | S-488211 | S-488211 is a freeze-dried injectable formulation containing the following two peptides, S-488204 (a DEPDC1-derived peptide) and S-488205 (an MPHOSPH1-derived peptide). |
Timeline
- Start date
- 2019-07-30
- Primary completion
- 2021-09-22
- Completion
- 2021-09-22
- First posted
- 2020-03-20
- Last updated
- 2022-01-26
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT04316689. Inclusion in this directory is not an endorsement.